AU5295500A - Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders - Google Patents
Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disordersInfo
- Publication number
- AU5295500A AU5295500A AU52955/00A AU5295500A AU5295500A AU 5295500 A AU5295500 A AU 5295500A AU 52955/00 A AU52955/00 A AU 52955/00A AU 5295500 A AU5295500 A AU 5295500A AU 5295500 A AU5295500 A AU 5295500A
- Authority
- AU
- Australia
- Prior art keywords
- treating
- gene delivery
- recombinant gene
- lysosomal storage
- delivery vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13652799P | 1999-05-28 | 1999-05-28 | |
US60136527 | 1999-05-28 | ||
PCT/US2000/014582 WO2000073482A1 (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5295500A true AU5295500A (en) | 2000-12-18 |
Family
ID=22473225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52955/00A Abandoned AU5295500A (en) | 1999-05-28 | 2000-05-26 | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1183384A1 (en) |
JP (1) | JP2003523174A (en) |
AU (1) | AU5295500A (en) |
CA (1) | CA2375123A1 (en) |
WO (1) | WO2000073482A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1343367A2 (en) * | 2000-12-20 | 2003-09-17 | K.U. Leuven Research & Development | Non-human animal disease models |
AU2002317701A1 (en) * | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
PL1740204T3 (en) * | 2004-04-01 | 2018-08-31 | Chiesi Farmaceutici S.P.A. | Medicinal use of alpha-mannosidase |
EP1818395A1 (en) | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
WO2018071898A1 (en) * | 2016-10-14 | 2018-04-19 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004799A (en) * | 1996-03-05 | 1999-12-21 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral DNA vaccines |
AU6424498A (en) * | 1997-03-18 | 1998-10-12 | Introgene B.V. | Methods and compositions for genetically modifying primate bone marrow cells |
WO1999036511A2 (en) * | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
-
2000
- 2000-05-26 CA CA002375123A patent/CA2375123A1/en not_active Abandoned
- 2000-05-26 WO PCT/US2000/014582 patent/WO2000073482A1/en not_active Application Discontinuation
- 2000-05-26 EP EP00937832A patent/EP1183384A1/en not_active Withdrawn
- 2000-05-26 JP JP2001500794A patent/JP2003523174A/en not_active Withdrawn
- 2000-05-26 AU AU52955/00A patent/AU5295500A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000073482A1 (en) | 2000-12-07 |
CA2375123A1 (en) | 2000-12-07 |
JP2003523174A (en) | 2003-08-05 |
EP1183384A1 (en) | 2002-03-06 |
WO2000073482A9 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3755900A (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
AU2001292881A1 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
AU4996300A (en) | Method of electroporation-enhanced delivery of active agents | |
HUP0002922A3 (en) | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors | |
AU2068501A (en) | Fibers providing controlled active agent delivery | |
AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
AU2001269923A1 (en) | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases | |
AU3358999A (en) | Chimeric adenoviral vectors for targeted gene delivery | |
AU9692198A (en) | Gene delivery compositions and methods | |
EP0710123A4 (en) | Adenovirus vectors for gene therapy sponsorship | |
AU8070298A (en) | Surface coatings for catheters, direct contacting diagnostic and therapeutic devices | |
AU1403199A (en) | Local delivery of therapeutic agents | |
GB9721909D0 (en) | Gene delivery vectors and their uses | |
AU2637100A (en) | Delivery system and methods for gene therapy | |
AU1261501A (en) | Compositions and methods for intranasal delivery of active agents to the brain | |
AU4744201A (en) | Systemic gene delivery vehicles for the treatment of tumors | |
AU5305000A (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses | |
AU5295500A (en) | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders | |
AU2003285346A1 (en) | Regulatory elements in the 5' region of the vr1 gene | |
AU3471400A (en) | Compositions and methods for controlled delivery of virus vectors | |
AU4675300A (en) | Recombinant laminin 5 | |
AU5960200A (en) | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease | |
EP1161547A4 (en) | Intravascular delivery of non-viral nucleic acid | |
AU1027501A (en) | Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies | |
AU1646201A (en) | Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |